JP Morgan Maintains Neutral on Upstream Bio, Raises Price Target to $9

Benzinga Newsdesk www.benzinga.com Positive 57.3%

Neg 0% Neu 0% Pos 57.3%

JP Morgan analyst Tessa Romero maintains Upstream Bio (NASDAQ:UPB) with a Neutral and raises the price target from $8 to $9.